Compare Abbott Laboratories (ABT) vs VanEck Vietnam ETF (VNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs VanEck Vietnam ETF — how do they compare? Abbott Laboratories trades at $110.78 (market cap $187.95B), while VanEck Vietnam ETF trades at $17.81. The key difference: Abbott Laboratories pays a 2.32% dividend while VanEck Vietnam ETF pays none. Which is the better fit depends on your goals.
| ABT | VNM | |
|---|---|---|
Market Cap | $187.95B | — |
Sector | Health | Sector/Thematic |
52-Week High | $136.62 | $19.80 |
52-Week Low | $82.57 | $16.34 |
Enterprise Value | $214.96B | — |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
VNM trades at $17.73, up 0.51% today, with a bullish technical signal driven by positive momentum indicators. The stock faces immediate resistance at $18, with support at $17. Recent news highlights Vietnam's economic challenges, including power grid strain and foreign capital outflows from Asian equities, potentially impacting the ETF's holdings.
Outlook remains cautious due to macroeconomic headwinds in Vietnam and underperformance relative to emerging markets. Investment opportunity hinges on FTSE Russell's EM reclassification attracting foreign inflows, but risks include heatwave-induced infrastructure stress and regional capital rotation away from AI-exposed markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About VanEck Vietnam ETF
VNM is the first and largest U.S.-listed ETF providing targeted exposure to the Vietnamese equity market. It tracks the MarketVector™ Vietnam Local Index, which includes publicly traded companies that are locally incorporated in Vietnam. It serves as a liquid, transparent vehicle for investors looking to participate in Vietnam's transition into a global manufacturing hub and its long-term potential for emerging market reclassification.
Read more on VNM →
